- MSdialog designed to provide people with multiple sclerosis (MS) and health care providers with injection history, treatment adherence information and health reports
- RebiSmart injection device provides updates with new version
The new RebiSmart will allow patients to self-inject. It will collect and store data such as injection times, dates and doses and send the information wirelessly to the secure MSdialog server. It is just a matter of placing the new RebiSmart in its transmitter and pressing a button.
Together with the new RebiSmart,
"Engaging and empowering patients through knowledge and technology may have the potential to improve outcomes by allowing patients to help monitor their own disease," said Dr.
Patients who use MSdialog can choose to receive email or SMS reminders to take their medication, and along with their nurses they can use MSdialog in between visits to their doctor to track the adherence and patient-reported outcomes. This information can save time for more patient-physician interaction during visits.
"Over the years,
RebiSmart was the first injection device in MS that records the date, time and dosage of each injection so that an accurate dosing history can be discussed with a patient, allowing physicians to monitor and improve patient adherence to therapy. The new RebiSmart offers updates to the original device, including a larger screen, new on-screen guide, graphical display of treatment adherence and a transmitter for wireless data transfer.
The new RebiSmart is used with Rebif multidose cartridges, each of which contains one week's worth of medicine. Interactive, on-screen instructions and signals guide patients through the injection process. Individually adjustable comfort settings give patients more flexibility with injection duration and depth, helping minimize discomfort and pain.
The new RebiSmart and MSdialog will be available in
Rebif (interferon beta-1a) is a disease-modifying drug used to treat relapsing forms of multiple sclerosis (MS) and is similar to the interferon beta protein produced by the human body. The efficacy of Rebif in chronic progressive MS has not been established. Interferon beta is thought to help reduce inflammation. The exact mechanism is unknown.
Rebif, which was approved in
Rebif can be administrated with the RebiSmart electronic auto-injection device, or with the RebiDose single-use disposable pen, or the manual multidose injection pen RebiSlide. Rebif can also be administered with the autoinjector Rebiject II or by manual injection using ready-to-use pre-filled syringes. These injection devices are not available in all countries.
Rebif should be used with caution in patients with a history of depression, liver disease and seizures. Most commonly reported side effects are flu-like symptoms, injection site disorders, elevation of liver enzymes and blood cell abnormalities. Patients, especially those with depression, seizure disorders, or liver problems, should discuss treatment with Rebif with their doctors.
About multiple sclerosis
Multiple sclerosis (MS) is a chronic, inflammatory condition of the central nervous system and is the most common, non-traumatic, disabling neurological disease in young adults. It is estimated that approximately two million patients have MS worldwide. While symptoms can vary, the most common symptoms of MS include blurred vision, numbness or tingling in the limbs and problems with strength and coordination. The relapsing forms of MS are the most common.
For more information, please visit www.merckserono.com.
All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.
Merck is a leading company for innovative and top-quality high-tech products in the pharmaceutical and chemical sectors. With its four divisions
[*] The exact correlation between MRI findings and the current or future clinical status of patients, including disability progression, is unknown.
Phone +1 781.681.2719
Most Popular Stories
- McDonald's Packages Coffee for National Distribution
- Uber Hires Obama Campaign Manager David Plouffe
- HTC Makes Windows Version of Flagship One Phone
- Rising Freight Prices Signal Global Recovery
- Russia Claims Ukraine Leaders Are Satanists, Jews or Maybe Even Scientologists
- Bob Marley Musical to Make Premiere in Baltimore
- Ballmer Steps Down From Microsoft Board
- Castro-Blanco Joins Fifth Street Finance Board
- Eric Holder Bringing Civil Rights Reminders to Ferguson
- Sprint Cancels Framily, Rolls Out New Data Pricing Plan